On November 9, 2026 AbCellera (Nasdaq: ABCL) reported financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes. On the strength of this data, we raised $200 million, bringing our available liquidity to approximately $900 million," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026."

Q3 2026 Business Summary and Program Updates

Announced positive top-line Phase 2 clinical trial data for ABCL635 that demonstrated significant reductions in the frequency and severity of moderate and severe vasomotor symptoms (VMS), a favorable tolerability profile, and significant improvements in sleep and patient global impression of change (PGI-C). AbCellera expects to initiate late-stage development for menopausal VMS in 2027. AbCellera is also expanding the indications for ABCL635 to include VMS caused by hormone suppression associated with breast and prostate cancer treatment. The initiation of clinical trials in these two populations is expected in 2027.
Completed a $200 million offering of common shares and pre-funded warrants.
Continued to advance ABCL386 and ABCL688 through IND-enabling activities.
Advanced the following three new programs in IND-enabling activities:
ABCL992, an investigational antibody drug candidate that is a next-generation half-life extended analog of ABCL635 for the treatment of VMS;
ABCL385, an investigational antibody drug candidate for an undisclosed indication in oncology; and
ABCL646, a potential first-in-class investigational antibody antagonist of an undisclosed ion channel target for the treatment of an undisclosed indication.
Generated a net loss of $40.8 million, compared to a net loss of $57.1 million in Q3 2025.
Ended the quarter with over $790 million in total cash balances and marketable securities, and over $890 million in total available liquidity to execute on AbCellera’s strategy.
Subsequent Event

Announced top-line data for the Phase 1 clinical trial of ABCL575, an investigational antibody drug targeting OX40 ligand for the treatment of atopic dermatitis and other autoimmune conditions. The Phase 1 study met all endpoints, demonstrating a favorable tolerability profile and a pharmacokinetic profile that supports an extended dosing interval. AbCellera currently does not plan to develop ABCL575 past Phase 1.
Discussion of Q3 2026 Financial Results

Revenue – Total revenue was $10.6 million, compared to $9.0 million in Q3 2025.
Research & Development (R&D) Expenses – R&D expenses were $43.5 million, compared to $55.0 million in Q3 2025.
Sales, General, & Administrative (SG&A) Expenses – SG&A expenses were $13.6 million, compared to $25.0 million in Q3 2025.
Net Loss – Net loss of $40.8 million, or $(0.13) per share on a basic and diluted basis, compared to net loss of $57.1 million, or $(0.19) per share on a basic and diluted basis, in Q3 2025.
Available Liquidity – Following the capital raise and positive year-to-date operating cashflow, AbCellera has over $790 million in total cash balances and marketable securities, and over $100 million in available non-dilutive government funding, bringing total available liquidity to over $890 million to execute on AbCellera’s strategy.
Business Metrics

At the end of Q3 2026, partners led 34 programs that AbCellera believes to be progressing and where AbCellera holds a downstream stake (down from 44 on December 31, 2025). In total, AbCellera held downstream stakes in 12 molecules in the clinic understood to be progressing on September 30, 2026.

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 3:00 p.m. Pacific Time / 2:00 p.m. Pacific Standard Time / 5:00 p.m. Eastern Standard Time.

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

(Press release, AbCellera, NOV 9, 2026, View Source [SID1234674513])

On November 9, 2026 Eilean Therapeutics, LLC ("Eilean"), a clinical-stage biotechnology company applying a hybrid AI/ML platform to the discovery of targeted protein degraders for cancer and immune-mediated disease, reported new safety and target-engagement data for ZE66‑0205, a first-in-class, orally available degrader of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), a central driver of NF-κB signaling in malignant B and T cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In GLP toxicology studies of up to three months’ duration, ZE66‑0205 was well tolerated in non-human primates at every dose tested, up to 500 mg/kg/day, with no adverse findings and near-complete MALT1 degradation. In the single-ascending-dose (SAD) portion of the ongoing healthy-volunteer study, ZE66‑0205 produced dose-dependent MALT1 degradation, reducing MALT1 protein in blood mononuclear cells by 57% at plasma exposures projected to be therapeutic.

On the strength of these results, Eilean is advancing two clinical studies in parallel: a healthy-volunteer study of safety, tolerability, pharmacokinetics (PK) and biomarkers, and a Phase 1b study in patients with relapsed or refractory B- and T-cell lymphomas and chronic lymphocytic leukemia (CLL).

Safety and target engagement

Primate safety through three months: In GLP studies in cynomolgus monkeys dosed at 30, 100 and 500 mg/kg/day, ZE66‑0205 produced no adverse effects on clinical signs, body weight, ECG, cardiovascular or respiratory parameters, clinical pathology, immune-cell subsets or organ histopathology. The no-observed-adverse-effect level (NOAEL) was the highest dose tested, 500 mg/kg/day.
Murine safety: In a 28-day GLP study, the NOAEL was likewise the highest dose tested (500 mg/kg/day), with no effects on central nervous system function or lymphocyte subsets.
Genetic toxicology and cardiac safety: ZE66‑0205 was negative in GLP Ames and chromosome-aberration assays and showed minimal hERG inhibition.
Primate target engagement: At all three doses, MALT1 protein in blood mononuclear cells fell by approximately 90% within 4–24 hours of the first dose and remained suppressed through Day 28. MALT1 returned to baseline after dosing stopped, confirming that the effect is reversible.
Human target engagement: In the SAD portion of the healthy-volunteer study, MALT1 in blood mononuclear cells fell dose-dependently, by 57% at 24–72 hours post-dose, before returning to baseline — again confirming reversibility. Plasma exposure at this dose exceeded the level projected to be effective from preclinical lymphoma models.
Human safety: ZE66‑0205 has been well tolerated to date, with no drug-related adverse events and no dose-limiting safety findings at doses achieving therapeutically relevant exposure. Dose escalation continues per protocol.
Clinical program: two studies in parallel

Study ZE66‑0205-0001 (healthy volunteers, Australia). A randomized, double-blind, placebo-controlled first-in-human study assessing safety, tolerability, PK and pharmacodynamics, the last measured as MALT1 levels in blood mononuclear cells.

Single ascending doses starting at 50 mg, with eight participants per cohort (six on active drug, two on placebo)
Additional cohorts evaluating higher doses and the effect of food on absorption
Phase 1b study (patients). An open-label, international, multicenter dose-escalation and expansion study in adults with relapsed or refractory B- or T-cell lymphoma or CLL/small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy.

Indications: activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL), including after CAR-T therapy; marginal zone lymphoma, including MALT lymphoma; follicular lymphoma; mantle cell lymphoma; Waldenström’s macroglobulinemia; CLL/SLL following BTK and BCL2 inhibitors; and peripheral T-cell lymphoma
Part A — dose escalation: once-daily oral dosing in 28-day cycles, beginning at a dose already cleared in healthy volunteers. Escalation follows a Bayesian optimal interval (BOIN) design guided by safety, PK and MALT1 degradation.
Part B — dose optimization and expansion: a randomized comparison of two doses, consistent with FDA Project Optimus guidance, to select the recommended Phase 2 dose
Endpoints: dose-limiting toxicities and adverse events (primary); PK, MALT1 degradation in blood and tumor biopsies, and NF-κB pathway biomarkers including IL-2 and IL-10 (secondary). Preliminary response is assessed using Lugano, iwCLL and IWWM-6 criteria.
Running both studies in parallel is designed to identify the optimal biologically active dose rapidly and to support initiation of Phase 2 in 2027.

Management comment

"Achieving upto a 57% dose dependent reduction in MALT1 after a single oral dosing in humans, alongside a clean three-month primate safety profile, is a significant milestone for ZE66‑0205," said Iain Dukes, D.Phil., Chief Executive Officer of Eilean Therapeutics. "Removing the MALT1 protein, rather than merely blocking its protease activity, shuts down both its scaffolding and its enzymatic roles in NF-κB signaling. Running our healthy-volunteer and patient studies in parallel allows us to move quickly toward the dose that delivers maximal target suppression for patients with lymphoma and CLL."

About MALT1 and ZE66‑0205

MALT1 is essential for NF-κB activation downstream of the B-cell and T-cell receptors. This pathway drives the survival, proliferation and drug resistance of many lymphoid cancers, including ABC-DLBCL and CLL that has progressed on BTK inhibitors. ZE66‑0205 is an oral, cereblon-based protein degrader. In preclinical studies it degraded MALT1 at low-nanomolar concentrations (DC50 of approximately 3 nM) with high selectivity across the proteome, and extended survival in a MALT1-dependent DLBCL model.

(Press release, Eilean Therapeutics, NOV 9, 2026, View Source [SID1234674511])

On November 9, 2026 Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) reported an agreement under which they will collaborate on the discovery of novel clinical candidates across a number of research programs in the field of oncology, potentially dermatology, and rare diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, XtalPi will use its integrated AI capabilities and robotics platform to de novo design and deliver novel small molecule therapeutics against undisclosed targets. Laboratoires Pierre Fabre will contribute with its expertise in disease biology, discovery, translational research, and clinical development to select and advance the most promising compounds, and will be responsible for subsequent clinical and commercial development.

The collaboration reflects the parties’ shared interest in exploring challenging and historically hard-to-drug targets—an area associated with significant unmet medical need and substantial opportunity in innovative drug discovery.

For Laboratoires Pierre Fabre, this agreement represents a strategic addition to its R&D roadmap, strengthening its drug discovery capabilities. It also advances XtalPi’s efforts to apply AI and robotics to de novo drug discovery. Together, the companies aim to accelerate the identification of high-quality clinical candidates across multiple research programs in oncology and potentially other therapeutic areas.

Raymond Zheng, Head of Integrated Drug Discovery at XtalPi said: "We are honored to enter into this collaboration with Laboratoires Pierre Fabre, a respected international pharmaceutical company. This partnership combines XtalPi’s AI and robotics capabilities with Laboratoires Pierre Fabre’s established therapeutic development expertise. We aim to advance promising preclinical candidates to benefit patients with unmet medical needs."

Francesco Hofmann, Head of Pharma Research and Development at Laboratoires Pierre Fabre said: "Partnering with XtalPi represents an important milestone for us. Leveraging the expertise of XtalPi on AI to accelerate the delivery of high-quality clinical candidates for multiple targets is a critical addition to our R&D Data and AI roadmap and to our discovery engine".

The agreement includes an upfront payment, multiple milestone payments and downstream economic participation; specific financial terms were not disclosed.

(Press release, Pierre Fabre, NOV 9, 2026, View Source [SID1234674510])

On November 9, 2026 Biond Biologics Ltd. ("Biond" or the "Company"), a private clinical-stage biopharmaceutical company developing first-in-class immunotherapies for cancer and immune-mediated diseases, reported that the first patient has been dosed in a first-in-human Phase 1 dose escalation clinical trial in advanced solid tumors evaluating BND-67, a novel antibody-based therapy designed to prevent CD28 shedding.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first patient was treated at the Institute of Oncology, Davidoff Center, Rabin Medical Center, Israel, one of multiple clinical sites participating in the study. The trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BND-67. The unique clinical design includes a lead-in BND-67 monotherapy treatment followed by combination therapy of BND-67 and anti-PD-1 therapy, in patients relapsing on anti-PD-1 therapy following prior clinical benefit, across selected oncology indications. The first patient completed BND-67 0.3 mg/kg monotherapy without any dose-limiting toxicities or infusion-related reactions and is now receiving BND-67 in combination with nivolumab once every two weeks (MOH_2026-04-14-015766).

"Patients who relapse after responding to immunotherapy represent a significant unmet medical need. BND-67 is based on a compelling biological rationale and targets a previously unexplored mechanism of immune dysfunction like CD28 shedding," said Professor Salomon Stemmer, M.D., Head of Research, Development and Innovation and Deputy Director of Davidoff Center at the Rabin Medical Center, Israel, and a clinical investigator in the trial. "We are pleased to participate in this first-in-human study and investigate its potential to improve outcomes for patients with advanced solid tumors."

"BND-67 opens an entirely new therapeutic avenue for cancer immunotherapy," said Giovanni Selvaggi, MD, Chief Medical Officer at Biond. "CD28 has long been viewed as a cornerstone for T-cell activation, yet no targeted therapy has successfully harnessed it without compromising safety. By preventing CD28 shedding, BND-67 is designed to preserve physiological CD28 signaling and potentiate anti-tumor immune response, without the systemic toxicity associated with CD28 agonism. The BND-67 0.3 mg/kg was shown to be safe and tolerable with sustained receptor occupancy." The Phase 1 lead-in design is intended to establish BND-67’s initial safety and tolerability profile while assessing early signals of clinical activity.

About BND-67 and CD28 Shedding

BND-67 is a first-in-class immunotherapy designed to inhibit pathological CD28 shedding, an immune evasion mechanism found across many types of cancers first described by Biond. CD28 is a critical co-stimulatory receptor required for effective T-cell activation, proliferation, and persistence. In cancer patients, CD28 can be cleaved from the surface of T cells, by specific matrix metalloproteases (MMPs) that are secreted from various cells including T cells and from the cancer cells, leading to impaired immune responses and reduced sensitivity to immunotherapies.

By preventing CD28 shedding, BND-67 is designed to enhance T-cell activation and expansion while selectively inhibiting regulatory T-cell differentiation and suppressive activity. Preclinical studies have demonstrated that BND-67 induces a potent and sustained anti-tumor immune response, both as a monotherapy and in combination with T-cell activating therapies including PD-1 inhibitors and T-cell engagers while demonstrating a favorable safety profile in animal models.

(Press release, Biond Biologics, NOV 9, 2026, View Source [SID1234674509])

On November 9, 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, reported financial results for the quarter ended September 30, 2026, and provided recent corporate highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027," said Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics. "We also initiated the Phase 1 trial of HWK-206, marking the advancement of all three of our original ADC programs into clinical development within the last 12 months. With its improved biparatopic design, HWK-206 has demonstrated enhanced preclinical antitumor activity compared to other SEZ6-targeted ADCs. Our global clinical development strategy is focused on efficiently evaluating how these preclinical attributes translate in patients with small-cell lung cancer."

Q3 2026 and Recent Operational Highlights:

Continued to advance the ongoing Phase 1 trials of HWK-007 and HWK-016.
HWK-007, a PTK7-targeting ADC, is being evaluated in patients with non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian cancer; and endometrial cancer (NCT07444814).
HWK-016, a MUC16-targeting ADC, is being evaluated in patients with advanced ovarian and endometrial cancers (NCT07470853).
Initiated the Phase 1 clinical trial of HWK-206 in the U.S. and received Fast Track designation from the U.S. Food and Drug Administration (FDA).
HWK-206 is a novel, biparatopic, SEZ6-targeting ADC utilizing the same TOP1i-linker payload as Whitehawk’s first two programs. HWK-206 is being developed initially for small-cell lung cancer (SCLC) and other neuroendocrine tumors.
Whitehawk submitted an Investigational New Drug (IND) application in China and anticipates activating its first clinical sites in China in Q1 2027.
The study is designed to evaluate an accelerated sequence of planned dose levels, starting at 3 mg/kg, informed by Whitehawk’s experience with HWK-007 and HWK-016. The initial dose-escalation portion will focus on patients with SCLC, providing an opportunity to evaluate HWK-206 against established clinical benchmarks.
Initial Phase 1 data from HWK-206 is expected by year-end 2027.
Presented real-world analyses supporting PTK7 as a durable ADC target in EGFR wild-type NSCLC at World Conference on Lung Cancer 2026. PTK7 expression remained stable following standard-of-care therapies, supporting its relevance as a target in second-line or later-line EGFR wild-type NSCLC.
Presented real-world analyses supporting MUC16 as a durable ADC target in ovarian cancer at International Gynecologic Cancer Society 2026. MUC16 expression remained high and stable following standard-of-care therapies, supporting its potential utility in both combination approaches and relapsed settings. High MUC16 expression was associated with poor real-world overall survival in high-grade serous ovarian carcinoma, the most common subtype of ovarian cancer.
Appointed Vijay Iyengar, MD, to Board of Directors. Dr. Iyengar, a former Incyte executive, brings extensive oncology, corporate strategy, business development and medical affairs experience to Whitehawk.
Q3 2026 Financial Results:

Cash, cash equivalents and short-term investments as of September 30, 2026, were $169.7 million as compared to $145.7 million as of December 31, 2025. Cash is anticipated to fund operations into 2H 2028 based on current plans.
Research and development expenses were $18.1 million for the three months ended September 30, 2026, as compared to $14.3 million for the three months ended September 30, 2025.
Net loss for the three months ended September 30, 2026, was $21.2 million as compared to $17.7 million for the three months ended September 30, 2025.
Upcoming Investor Conferences:

Jefferies Global Healthcare Conference in London – management will participate in investor meetings, and Dave Lennon will participate in a fireside chat on November 16, 2026, at 9:30 AM GMT.
Piper Sandler 38th Annual Healthcare Conference – management will participate in investor meetings, and Dave Lennon will present a corporate overview on December 2, 2026, at 1:30 PM ET.
A live webcast of the fireside chat and presentation can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the events.

(Press release, Whitehawk Therapeutics, NOV 9, 2026, View Source [SID1234674508])